Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
MMWR Morb Mortal Wkly Rep ; 67(38): 1068-1071, 2018 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-30260942

RESUMEN

Vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine is recommended for all pregnant women to protect infants who are too young for vaccination from severe pertussis-related outcomes (1-3). However, Tdap vaccine coverage among pregnant women remains suboptimal in California (4). California mothers whose infants developed pertussis in 2016 and their prenatal care providers were interviewed to ascertain possible reasons for low Tdap vaccine coverage. Mothers who were offered Tdap vaccination on-site during a routine prenatal visit were more likely to be vaccinated than were mothers who were referred off-site for vaccination. Mothers insured by Medicaid were less likely to receive Tdap vaccine than were mothers with private insurance, even when the vaccine was stocked on-site. Nearly all vaccinated mothers received Tdap vaccine in their prenatal clinic. Incorporating Tdap vaccination into routine prenatal care visits is an effective means to increase prenatal Tdap vaccination coverage.


Asunto(s)
Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/administración & dosificación , Accesibilidad a los Servicios de Salud , Mujeres Embarazadas/psicología , Atención Prenatal , Vacunación/estadística & datos numéricos , Tos Ferina/epidemiología , Tos Ferina/prevención & control , California/epidemiología , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/provisión & distribución , Femenino , Humanos , Lactante , Seguro de Salud/estadística & datos numéricos , Medicaid/estadística & datos numéricos , Embarazo , Sector Privado , Investigación Cualitativa , Derivación y Consulta/estadística & datos numéricos , Negativa del Paciente al Tratamiento/estadística & datos numéricos , Estados Unidos
2.
Expert Rev Vaccines ; 15(12): 1575-1582, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27345296

RESUMEN

INTRODUCTION: The manufacture of DTP-backboned combination vaccines is complex, and vaccine quality is evaluated by both batch composition and conformance of manufacturing history. Since their first availability, both the manufacturing regulations for DTP combination vaccines and their demand have evolved significantly. This has resulted in a constant need to modify manufacturing and quality control processes. Areas covered: Regulations that govern the manufacture of complex vaccines can be inconsistent between countries and need to be aligned with the regulatory requirements that apply in all countries of distribution. Changes in product mix and quantities can lead to uncertainty in vaccine supply maintenance. These problems are discussed in the context of the importance of these products as essential public health tools. Expert commentary: Increasing demand for complex vaccines globally has led to problems in supply due to intrinsically complex manufacturing and regulatory procedures. Vaccine manufacturers are fully engaged in the resolution of these challenges, but currently changes in demand need ideally to be anticipated approximately 3 years in advance due to long production cycle times.


Asunto(s)
Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/inmunología , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/provisión & distribución , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas , Humanos , Control de Calidad , Vacunas Combinadas/inmunología , Vacunas Combinadas/provisión & distribución
3.
J Adolesc Health ; 44(4): 387-93, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19306798

RESUMEN

PURPOSE: In 2006 the Advisory Committee on Immunization Practices (ACIP) recommended replacement of the adolescent tetanus and diphtheria toxoids (Td) booster with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). We examined the degree to which pediatricians and family practitioners have adopted this recommendation. METHODS: National mail-based survey of a random sample of 725 pediatricians and 725 family practitioners from January through March, 2007. RESULTS: Overall response rate was 60%. The majority of respondents indicated they routinely recommended Tdap to adolescents at the preferred age for vaccination, 11-12 years old (87%), and also for "catch up" vaccination among adolescents 13-18 years old (89%). In bivariate analyses, pediatrician specialty, specialty society membership, stocking Tdap in the office, and prior experience diagnosing adolescent pertussis were associated with routinely recommending Tdap to adolescents. In multivariable models adjusting for these factors simultaneously, only pediatrician specialty (OR = 4.8, 95% CI = 2.5-9.3) and stocking Tdap in the office (OR = 14.5, 95% CI = 7.5-28.5) remained significantly associated with routine recommendation. Pediatricians were significantly more likely than family practitioners to accept shorter time intervals for administering Tdap following Td vaccination, and to co-administer Tdap with MCV4. Lack of adolescent visits was the most commonly cited major barrier to adolescent Tdap administration. CONCLUSIONS: Based on self report, our results indicate the majority of physicians have adopted recent recommendations from the ACIP to administer Tdap to adolescents. However, specialty-based disparities in attitudes and practices persist, suggesting that ongoing efforts are needed to motivate physicians to recommend this vaccine to adolescents and to clarify how to integrate Tdap with other adolescent vaccinations.


Asunto(s)
Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/uso terapéutico , Médicos de Familia , Pautas de la Práctica en Medicina , Adolescente , Adulto , Actitud del Personal de Salud , Niño , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/provisión & distribución , Femenino , Encuestas de Atención de la Salud , Humanos , Masculino , Persona de Mediana Edad , Estados Unidos , Adulto Joven
4.
Hum Vaccin ; 3(4): 130-4, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17643067

RESUMEN

Availability of combined tetanus-diphtheria-acellular pertussis (Tdap) vaccines for adults offers a new pertussis prevention strategy for the US. Successful uptake of Tdap vaccine will depend partly on the attitudes and practices of primary care physicians, including their experience with Td boosters. We conducted a mail survey in August 2005 of a national random sample of 399 family physicians (FPs) and 399 general internists (IMs) to assess practices related to Td boosters, clinical experience with pertussis, and attitudes toward a potential Tdap vaccine recommendation for adults. The response rate was 49% (52% FPs, 46% IMs). Among 336 eligible respondents, half reported having clinical experience with pertussis. Most (81%) would recommend Tdap vaccine for their adult patients, and 73% support targeting adults likely to come in close contact with infants. Attitudes toward a potential Tdap vaccine recommendation differed by whether providers stock and administer Td boosters. We conclude that adult primary care providers in the US are likely to recommend Tdap vaccine to their adult patients, in concordance with recent national recommendations. Future research should assess the extent to which barriers impede adoption of Tdap vaccine recommendations.


Asunto(s)
Actitud del Personal de Salud , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/administración & dosificación , Médicos de Familia/psicología , Pautas de la Práctica en Medicina , Adulto , Anciano , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/economía , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/provisión & distribución , Medicina Familiar y Comunitaria , Encuestas de Atención de la Salud , Humanos , Medicina Interna , Persona de Mediana Edad , Encuestas y Cuestionarios , Estados Unidos
5.
Am J Public Health ; 96(4): 697-701, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16507733

RESUMEN

OBJECTIVES: We determined the effect of national vaccine shortages on coverage with 4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine for American Indian/Alaska Native (AIAN) children. METHODS: Data on DTaP coverage for children aged 19 to 27 months were abstracted from Indian Health Service (IHS) immunization reports. Coverage with the fourth DTaP dose (DTaP4) was compared for different periods to determine coverage levels before, during, and after the shortage. Data were stratified geographically to determine regional variation. RESULTS: AIAN children experienced a significant decline (14.8%) in DTaP4 coverage during the shortage. Considerable variation was seen among IHS regions (declines ranged from 4.5% to 26.5%). CONCLUSIONS: AIAN children included in IHS immunization reports experienced a greater decline in DTaP4 coverage during the shortage than the decline reported nationally for children receiving vaccine at public clinics (14.8% vs 6%). Variations in the decline in coverage highlight possible inequities in vaccine supply and distribution and in implementation of vaccine shortage recommendations. We must identify ways to ensure more equitable vaccine distribution and consistent implementation of vaccine recommendations to protect all children from vaccine-preventable diseases.


Asunto(s)
Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/provisión & distribución , Indígenas Norteamericanos , Inuk , Vacunación , Preescolar , Humanos , Lactante , Vacuna Antipolio de Virus Inactivados/provisión & distribución , Estados Unidos , United States Indian Health Service/organización & administración
6.
Am J Public Health ; 96(4): 691-6, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16507734

RESUMEN

OBJECTIVES: We determined the effect of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) and measles, mumps, rubella (MMR) vaccine shortages on timeliness of the third dose of DTaP (DTaP3), the fourth dose of DTaP (DTaP4), and the first dose of MMR (MMR1) among subgroups of preschool children. METHODS: Data from the 2001 and 2002 National Immunization Surveys were analyzed. Children age-eligible to receive DTaP3, DTaP4, or MMR1 during the shortages were considered subject to the shortage, and those not age-eligible were not subject to the shortage; timeliness of vaccinations was compared. RESULTS: Among children vaccinated only at public clinics, children residing outside metropolitan statistical areas, and children in the Southern Census Region, those age-eligible to receive DTaP4 during the shortage were less likely to be vaccinated by 19 months of age than children not subject to the shortage. CONCLUSIONS: There was notable disparity in the effects of the recent vaccine shortages; children vaccinated only in public clinics, in rural areas, or in the Southern United States were differentially affected by the shortages.


Asunto(s)
Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/provisión & distribución , Vacuna contra el Sarampión-Parotiditis-Rubéola/provisión & distribución , Vacunación , Preescolar , Humanos , Lactante
8.
An. pediatr. (2003, Ed. impr.) ; 58(supl.5): 56-62, jun. 2003. tab, ilus
Artículo en Español | IBECS | ID: ibc-141169

RESUMEN

En la actualidad disponemos de un número de vacunas que son cada día más numerosas, seguras y eficaces. Este hecho, que supone un gran avance, también plantea problemas de aceptación por el gran número de pinchazos y otros inconvenientes que supone su administración. La disponibilidad de vacunas hexavalentes (DTPa/VPI/Hib/HB) no sólo combina 6 vacunas en una sola, con lo que mejora la aceptación por parte de los padres y las tasas de cobertura, sino que también permite abandonar la VPO para sustituirla por la VPI evitando el riesgo de poliomielitis paralítica asociada a vacuna (PPAV) y, por otra parte, incluir la anti-pertussis acelular (Pa) con que disminuye muy significativamente la reactogenicidad de este componente. Sin ninguna duda, la disposición de vacunas hexavalentes supone un avance extraordinariamente importante en el campo de las inmunizaciones y permitirá con su incorporación en los calendarios vacunales que éstos sean más completos, eficaces y cómodos de aplicar. El CAV de la AEP propondrá en un futuro muy próximo un nuevo calendario vacunal en el que la vacuna hexavalente supondrá una mejora de enorme trascendencia (AU)


No disponible


Asunto(s)
Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , /normas , Vacunas Combinadas/inmunología , Vacunación/métodos , Vacunación/normas , Programas de Inmunización/métodos , Programas de Inmunización/organización & administración , Programas de Inmunización , Vacunas/provisión & distribución , Vacunas Conjugadas/inmunología , Vacunas Conjugadas/normas , Vacunas Combinadas/normas , Programas de Inmunización/normas , Programas de Inmunización/tendencias , Cobertura de Vacunación , Bordetella pertussis/inmunología , Vacuna contra la Tos Ferina/inmunología , Vacuna contra Difteria, Tétanos y Tos Ferina/inmunología , Vacuna contra Difteria, Tétanos y Tos Ferina/provisión & distribución , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/provisión & distribución
15.
MMWR Morb Mortal Wkly Rep ; 50(10): 189-90, 2001 Mar 16.
Artículo en Inglés | MEDLINE | ID: mdl-11280456

RESUMEN

During the last quarter of 2000, the U.S. Public Health Service learned of a shortage of tetanus and diphtheria toxoids (Td) and tetanus toxoid (TT) resulting from decreased production of these vaccines by the two U.S. manufacturers. Previously published recommendations outlined priorities for use of the limited supply of Td and TT. The shortage was expected to be resolved by early 2001; however, on January 10, 2001, Wyeth Lederle (Pearl River, New York) announced it had stopped production of tetanus toxoid-containing products. Although a small amount of Td is produced by the University of Massachusetts for local distribution, Aventis Pasteur (Swiftwater, Pennsylvania) is now the sole nationwide distributor of Td and TT. Aventis Pasteur is shipping limited quantities of vaccine to assure a wide distribution of available doses.


Asunto(s)
Toxoide Diftérico/provisión & distribución , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/provisión & distribución , Vacuna contra la Tos Ferina/provisión & distribución , Toxoide Tetánico/provisión & distribución , Estados Unidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA